|1.||Saito, Mitsuru: 17 articles (10/2015 - 12/2006)|
|2.||Marumo, Keishi: 8 articles (10/2015 - 07/2010)|
|3.||Franke, S: 8 articles (05/2014 - 10/2002)|
|4.||Schalkwijk, Casper G: 7 articles (01/2015 - 03/2009)|
|5.||Stein, Günter: 7 articles (01/2008 - 05/2002)|
|6.||Franke, Sybille: 7 articles (01/2008 - 05/2002)|
|7.||Stein, G: 6 articles (09/2007 - 02/2003)|
|8.||Takahashi, Masaaki: 6 articles (04/2007 - 01/2002)|
|9.||Lindholm, Bengt: 5 articles (07/2015 - 05/2003)|
|10.||Scheijen, Jean L J M: 5 articles (01/2015 - 03/2009)|
|1.||Schizophrenia (Dementia Praecox)
01/01/2012 - "We found that seventeen schizophrenia (approximately 17.4%) showed increases in plasma pentosidine content although they have no physical complications, and concomitantly marked decrease of pyridoxal levels was found in schizophrenia. "
11/01/2014 - "Thus, extremely high pentosidine levels in a portion of patients may be caused by higher daily antipsychotic doses, whereas pyridoxal levels were lower in schizophrenia and increased according to the clinical course. "
09/01/2014 - "In June 2010, we reported on idiopathic carbonyl stress in a subpopulation of schizophrenia patients, leading to a failure of metabolic systems with plasma pentosidine accumulation and serum pyridoxal depletion. "
06/01/2010 - "Most patients with schizophrenia who carried the genetic defects exhibited high pentosidine and low vitamin B(6) levels in contrast with control subjects with the genetic defects, suggesting the existence of compensatory mechanisms. "
06/01/2010 - "To examine whether plasma levels of pentosidine and serum vitamin B(6) are altered in patients with schizophrenia and to evaluate the functionality of GLO1 variations linked to concomitant carbonyl stress. "
04/01/2005 - "In addition, a period of ten months of acceptable metabolic control is not enough to normalize pentosidine levels in diabetics, thus emphasizing the need for a longer period of improved metabolic control to reduce both this parameter and the burden of chronic diabetic complications."
09/01/1998 - "The present study was undertaken to assess the factors determining plasma total pentosidine level in diabetic patients and the possible relation between plasma pentosidine level and diabetic complications. "
03/19/2011 - "Pentosidine has a pivotal role in diabetic complications, probably as a consequence of the diverse properties of this compound, which alters the structure and function of molecules in biological systems. "
03/19/2011 - "[Pentosidine: a new biomarker in diabetes mellitus complications]."
07/01/1993 - "These results demonstrate that urinary pentosidine, especially in free form, could be a useful marker for the assessment of diabetes and diabetic complications."
01/01/2008 - "In Group I, there was a significant decrease in the plasma level of ADMA (from 2.5 +/- 0.5 to 1.3 +/- 0.4 micromol/l, P < 0.01), but ADMA remained unchanged in Group II. A further remarkable finding in Group I was reduction in the plasma concentration of pentosidine (from 480 +/- 170 to 320 +/- 120 microg/l, P < 0.01) and decrease of proteinuria (from 3.8 +/- 2.24 to 1.6 +/- 1.0 g/24 h, P < 0.02). "
10/01/2005 - "In unilateral proteinuria, pentosidine was similar in non-proteinuric and proteinuric kidneys. "
10/01/2005 - "Renal accumulation of pentosidine in non-diabetic proteinuria-induced renal damage in rats."
05/01/2003 - "This view is supported by the correlation found between renal pentosidine content and proteinuria. "
07/01/1993 - "NEWLY OBSERVED FINDINGS: Significant elevation of pentosidine (P = 0.025) was found in subjects with microalbuminuria or gross proteinuria (73.03 +/- 9.47 vs 76.46 +/- 6.37 pmol/mg col) when compared with normal (56.96 +/- 3.26 pmol/mg col). "
04/01/2010 - "We demonstrate a reduction in enzymatic divalent immature and trivalent pyridinium cross-links and an increase in the nonenzymatic cross-link, pentosidine (Pen), in rabbits with methionine (Met)-induced hyperhomocysteinemia. "
05/01/2011 - "Hyperglycemia, oxidative stress, carbonyl stress, and hyperhomocysteinemia induce the reduction in beneficial enzymatic cross-links and the accumulation of disadvantageous non-enzymatic cross-link, Advanced glycation end products (AGEs, Pentosidine) in bone. "
09/01/2009 - "Hyperglycemia, oxidative stress, and hyperhomocysteinemia induce the reduction in enzymatic cross-links and the accumulation of non-enzymatic cross-link, Advanced glycation end products (AGEs, Pentosidine) in bone. "
07/01/2010 - "In a case-controlled study, a significant reduction in the actual amount of enzymatic cross-links and a marked increased in advanced glycation end products cross-link, pentosidine, in bone from patients with post-menopausal osteoporotic hip fracture showing hyperhomocysteinemia (Saito M, Calcif Tissue Int 2006). "
03/01/2010 - "Oxidative stress induced by hyperhomocysteinemia deteriorates bone quality in terms of collagen enzymatic and non-enzymatic cross-links such as pentosidine (Saito M, Osteoporos Int [REVIEW], 2010). "
08/31/2004 - "In comparison to patients with a normal creatinine clearance, patients with a reduced creatinine clearance had not only higher creatinine-concentrations in the sera and higher values of albuminuria but also significantly higher pentosidine levels. "
01/01/2015 - "Although statin add-on therapy did not show additive renal protective effects, the diet therapy as well as the diet-plus-statin therapy could contribute to the reduction in plasma pentosidine in CKD patients with albuminuria and dyslipidemia."
01/01/1997 - "Our results show that oral administration of low-dose arginine reduces kidney collagen accumulation as reflected by kidney hydroxyproline, cross-linking as reflected by pentosidine, lipid peroxidation, glycoxidation as reflected by carboxymethyl lysine, kidney weight and albuminuria in the diabetic kk mouse. "
01/01/1997 - "Aminoguanidine reduced albuminuria by 70% after 4 months, and both guanidines 1) normalized aortic pentosidine levels and renal collagenase-soluble collagen, 2) had no effect on glycated hemoglobin levels or collagen-associated fluorescence (in aorta, kidney, or skin), and 3) had little or no effect on regional albumin permeation. "
|1.||Biological Markers (Surrogate Marker)
|2.||Advanced Glycosylation End Products
|5.||Vitamin B 6
|1.||Diet Therapy (Therapy, Diet)
|2.||Renal Dialysis (Hemodialysis)
|3.||Transplantation (Transplant Recipients)
|4.||Renal Replacement Therapy (Therapies, Renal Replacement)